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Invasive Mechanical Ventilation of COVID-19 ARDS Patients
Ventilación mecánica invasiva de pacientes con SDRA por COVID-19
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Abstract
The purpose of this review article is to analyse evidence on the use of ventilatory strategies 
and associated cointerventions in adult patients with COVID-19 induced acute respiratory 
distress syndrome (ARDS) and to provide treatment recommendations based on these 
interventions. For each recommendation mentioned, it is important to consider the quality of 
the evidence reviews thoroughly before applying these recommendations to specific 
clinical situations or policy decisions. No guideline or recommendations can consider all the 
compelling clinical features of individual patients, as they are unique. Thus, it is imperative 
that clinicians, patients, policy makers, and other stakeholders should not regard these 
recommendations as mandatory. However, this review article, impartially discusses the 
nuances of treatment available and management protocols followed in many centres 
around the world for the consumption of all treating physicians.
Keywords: Covid-19, mechanical ventilation, ICU.
Resumen
El propósito de este artículo de revisión es analizar la evidencia sobre el uso de estrategias 
ventilatorias y cointervenciones asociadas en pacientes adultos con síndrome de dificultad 
respiratoria aguda (SDRA) inducido por COVID-19 y brindar recomendaciones de 
tratamiento basadas en estas intervenciones. Para cada recomendación mencionada, es 
importante considerar la calidad de las revisiones de la evidencia a fondo antes de aplicar 
estas recomendaciones a situaciones clínicas específicas o decisiones políticas. Ninguna 
guía o recomendación puede considerar todas las características clínicas convincentes de 
los pacientes individuales, ya que son únicas. Por lo tanto, es imperativo que los médicos, 
los pacientes, los responsables políticos y otras partes interesadas no consideren estas 
recomendaciones como obligatorias. Sin embargo, este artículo de revisión analiza de 
manera imparcial los matices del tratamiento disponible y los protocolos de manejo 
seguidos en muchos centros alrededor del mundo para el consumo de todos los médicos 
tratantes.
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Introduction
A novel coronavirus was identified in Wuhan, China 
in December 2019, causing atypical pneumonia 
and rapidly spreading resulting in a pandemic. The 
World Health Organization designated the term 
COVID-19 (Coronavirus Disease 2019) for this 
pandemic. COVID-19 is caused by the severe acute 
respiratory syndrome coronavirus 2 (SARS-CoV-2). 
The major morbidity and mortality from COVID-19 is 
attributed to the acute viral pneumonitis that 
progresses to acute respiratory distress syndrome 
(ARDS).
Definition of ARDS:
COVID-19 ARDS (CARDS) is diagnosed when 
someone with a confirmed COVID-19 infection 
meets the Berlin 2012 ARDS diagnostic criteria(1), 
which include:
(i)    Acute hypoxemic respiratory failure; 
(ii) Presentation within 1 week of worsening 
respiratory symptoms; 
(iii) Bilateral airspace disease on chest x-ray, 
computed tomography (CT) or ultrasound that 
is not fully explained by effusions, lobar or lung 
collapse, or nodules; and 
(iv) Cardiac failure is not the primary cause of 
acute hypoxemic respiratory failure
This article will attempt to discuss the management 
of patients who develop ARDS due to COVID-19.
Methods
We convened an interprofessional panel with a 
broad sample of anaesthesiologists, clinical 
epidemiologists, paediatricians, internal medicine 
specialists, psychiatrist, radiologist and methodo-
logists to evaluate various studies with respect to 
COVID-19. We then had a face-to-face discussion 
on the same in our hospital before summarising our 
understanding. We evaluated existing systematic 
reviews from our search in MEDLINE, EMBASE, 
Cochrane Registry of Controlled Trials, Database of 
Abstracts of Reviews of Effects (OvidSP), CINAHL 
(EBSCOHost), and Web of Science (Thomson 
Reuters) from the date of the last systematic review 
to December 2020, without language restrictions. 
Panel members were also asked to highlight any 
additional studies not identified by the search. 
Recommendations are either “strong” or “conditio-
nal” according to the GRADE approach(2). We used 
the GRADE phrases “we recommend” for strong 
recommendations and “we suggest” for conditional 
recommendations. 
Manuscript was prepared by the writing committee 
(S.S, V.S) drafted the guideline document for 
subsequent electronic review by the entire panel. 
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The entire panel had the opportunity to correct 
factual or interpretative errors. The final approved 
version was then submitted.
Oxygenation & ventilation for CARDS (CARDS) 
patients
CARDS follows an anticipated time course, with a 
median time to intubation of 8 - 10 days after 
symptom onset (3). It is therefore imperative to 
constantly monitor patients for the development of 
ARDS as the day of infection progresses. The 
primary strategy for COVID-19 patients is 
supportive care, which includes oxygen therapy for 
hypoxemic patients. Oxygen therapy is instituted if 
respiratory rate is of 30 breaths/min or above and/or 
SpO2 of ≤93% on breathing air(4).
COVID-19 patients sometimes present with “silent 
or happy hypoxia” (atypical clinical features like 
feeling of calm and sense of wellbeing even in 
presence of significant level of hypoxia). The reason 
for this is the presence of low carbon dioxide levels 
(severe hypocapnic hypoxia) in blood, typically 
found in high altitude sickness(5). Atypical findings 
like these confuse treating physicians to intubate or 
not to intubate. Mechanical ventilation of COVID-19 
patients with ARDS (CARDS) is an unprecedented 
and challenging task as these patients usually have 
non homogenous lung pathology that requires a 
targeted lung-protective ventilation strategy to 
improve outcome. Most patients of CARDS require 
timely institution of mechanical ventilation. Undue 
delay in intubation and invasive mechanical 
ventilation will be detrimental to the patient and the 
risk of contagion spread to healthcare workers is 
high(6). A low threshold for intubation should be 
considered if the clinical condition of the patient 
deteriorates even with increase oxygen supplemen-
tation at high flow and at high FiO2.
Non invasive modes
High-flow nasal oxygen therapy (HFNO) is used as 
first-line treatment(3) for respiratory failure and 
mild-moderate ARDS. Non-Invasive Ventilation 
(NIV) is only recommended for patients with failed 
HFNO. NIV provides benefit via PEEP, to patients 
with mild-moderate ARDS by reducing the 
respiratory load and intubation rate, but it can cause 
significant aerosol generation.
High-flow nasal cannula (HFNC) for HFNO is 
effective in improving oxygenation, but due to 
reports of high amount of aerosol dispersion it was 
not recommended initially. However further studies 
in patients with acute hypoxemic respiratory failure, 
HFNC was proven to avoid intubation compared to 
conventional oxygen devices, and the scientific 
evidence of generation and dispersion of bio-
aerosols via HFNC showed a similar risk to 
standard oxygen masks. HFNC prong with a 
surgical mask on the patient's face is thus a 
reasonable modality to benefit hypoxemic COVID-
19 patients and avoid intubation(7). HFNC therapy 
essentially is an oxygen supply system capable of 
delivering up to 100% humidified and heated 
oxygen at a flow rate of up to 60 litres per minute. All 
settings are controlled independently allowing for 
greater confidence in the delivery of supplemental 
oxygen as well as better outcomes when used(8).
Prone Positioning for Non-intubated Patients : 
Although prone positioning has been shown to 
improve oxygenation and outcomes in patients with 
moderate-to-severe ARDS who are receiving 
mechanical ventilation, there is less evidence 
regarding the benefit of prone positioning in awake 
patients who require supplemental oxygen without 
mechanical ventilation(9).
Precautions and procedures followed while 
intubation of COVID-19 patients
Airway management and intubation in COVID-19 
patients is an aerosol generating procedure and is 
associated with increased risk of viral transmission 
to the health care providers. Hence, a high level of 
attentiveness is necessary to prevent infection 
when intubation is performed. Safety of patients and 
health care workers can be ensured by the following 
precautionary measures(10).
1. Health care professional should take airborne 
precautions with a standard level 3 protection to 
be donned while performing intubation. The 
recom-mended sequence for donning of 
personal protective equipment (PPE) is as 
follows: hand sanitisation/washing → head cap 
→ protective N95 mask → surgical masks → full 
body isolation gown → disposable inner gloves 
→ goggles → protective clothing → disposable 
outer gloves → shoe covers → disposable gown 
→ disposable outermost gloves → full head 
hood or face shield(11).
2. For intubation, the acronym OH–MSMAID 
(Oxygen, Helper, Monitor, Suction, Machine, 
Airway devices, Intravenous access, and Drugs) 
can be used to ease of remembrance(12).
3. Tracheal intubation should be performed by the 
most experienced anaesthesiologist, in an 
airborne infection isolation room, preferably in a 
negative pressure room to ensure patient safety 
and HCW (Health care worker).
4. The number of health care provider in the room 
prior to intubation should be limited.
5. Use 3-5 minutes of pre-oxygenation with 100% 
oxygen is mandatory as these critical patients 
have poor oxygen reserve(13).
6. Spontaneous ventilation should be preserved 
and as much as possible, assisted bag mask 
ventilation during preoxygenation should be 
avoided.
7. RSI (rapid sequence intubation) technique is to 
be recommended to avoid manual ventilation of 
the patient's lungs and prevent potential 
aerosolization of the virus from the airways. A 
COVID aerosol barrier intubation box can be 
used to shield aerosols(14).
8. Use both hands to hold the mask to ensure a tight 
seal using the V-E technique rather than the C-E 
technique with one hand.
9. Video laryngoscope should be preferred for 
intubation as it increases the distance between 
the patient and anaesthesiologist.
10. Airway management should be safe, accurate 
and should be done within 15-20 seconds. 
11. After tracheal intubation, clamp the ETT 
(endotracheal tube) and inflate the cuff before 
instituting mechanical ventilation.
12. Viral and HME filter must be connected between 
endotracheal tube and circuit.
12. Proper tube placement can be confirmed by 
EtCO2 monitoring, visible bilateral chest rise 
and routine 5 point auscultation is preferably 
avoided to confirm tube placement.
13. Supraglottic airway devices (SGAD) should be 
used in CICO (Can`t intubate and can`t 
oxygenate) situations only and bedside 
tracheostomy should be considered as early as 
possible.
14. If intubation is required while transporting 
patients with CARDS, it must be ensured that all 
protocols mentioned above should be adhered 
to(15).
Mechanical ventilation
Mechanical ventilation of COVID-19 patients with 
ARDS is challenging as these patients usually have 
a non-homogenous lung pathology. This requires a 
targeted lung-protective ventilation strategy to 
improve the outcome.
Indications for Mechanical Ventilation
The indications for mechanical ventilation in 
COVID-19  are as follows(7): - 
1. Acute hypoxic respiratory failure with severe 
respiratory distress.
2. Worsening hypoxia associated with increased 
laboured breathing.
3. Increase work of breathing associated with use of 
accessory muscles of respiration. 
4. Failure to maintain Spo  >90% with >50 L/minute 2
of high flow oxygen with HFNO or with maximal 
supplemental oxygen(16).
5. Hypoxia with altered mental status and failure to 
maintain airway patency.
6. Patient with multiorgan failure, persistent 
hemodynamic instability requires vasopressor 
support, or those with multiple comorbidities like 
(DM, Cardiovascular disease, hypertension, 
advanced age, frailty, cancer or chronic 
respiratory disease).
7. Arterial PH <7.3 with PaCO  > 50mm Hg.2
8. PaO /FiO  < 200 (17).2 2
9. High respiratory rate with persistent thoracoab-
dominal asynchrony or paradoxical respiration.
10. Low ROX index (< 4.88) with patient on HFNC. 
(The ROX index(18) defined as the ratio of 
Spo2/FiO2 to respiratory rate and it has been 
used as a predictor of the intubation need in 
patients received HFNC oxygen therapy. A ROX 
index ≥ 4.88 after HFNC initiation is associated 
with a lower risk for intubation.)
Indications for intubation and mechanical ventila-
tion in COVID-19 patients are not limited to the 
above mentioned conditions and should be case-
specific, and at the discretion of the treating 
physician(19).
Ventilatory strategy for CARDS
The optimal time to intubate COVID-19 patients is 
still not clear. Mechanical ventilation should be 
considered if a COVID-19 patient develops 
moderate to severe ARDS (PaO /FiO  < 200) to 2 2
prevent P- SILI (Patient self-induced lung injury) 
and viral transmission to health care provider [6]. 
Endotracheal intubation and invasive mechanical 
ventilation are to be considered on priority in ARDS 
patients who are acutely deteriorating in spite of 
supplemental oxygen therapy with HFNC. Non-
intubated spontaneously breathing ARDS patients 
are at increased risk of P-SILI due to high intake of 
inhaled tidal volume. Therefore, oesophageal 
pressure measurement by manometer can be used 
in spontaneously breathing, non-intubated patients 
to estimate the time for intubation(20). The risk of 
infection to the HCW remains a concern. The 
oesophageal pressure between 5 to 10 cmH2o is 
generally well tolerated. However, if pressure goes 
more than 15 cmH2O, then risk of P-SILI increases 
and therefore intubation should be carried out as 
soon as possible. If oesophageal manometry is not 
available, then change in CVP (centre venous 
pressure) with respiration or clinical assessment of 
excessive inspiratory effort for increased work of 
breathing to be considered(21).
 
Mortality is very high (67%) for CARDS patients on 
mechanical ventilation (22). An inappropriate 
ventilatory strategy in ARDS patients can lead to 
VILI (Ventilator induced lung injury) which includes 
barotrauma (high airway pressure), volutrauma, 
atelectrauma, biotrauma, myotrauma (diaphrag-
matic injury) and oxytrauma (oxygen free radicles).
Non COVID -19 ARDS has two sub phenotypes 
identified based on the ARMA and ALVEOLI trial. 
They respond differently to PEEP, liberal fluid 
therapy and can be identified with notable precision 
using four biomarkers: interleukin-6, interferon 
gamma, angiopoietin 1/2, and plasminogen 
activator inhibitor-1 (23)(24)-
(a) Hyperinflammatory type- This type is 
associated with higher levels of inflammatory 
biomarkers, high vasopressor use, high sepsis, 
lower serum bicarbonate and have worst 
outcome in terms of mortality, ventilator free 
days and organ-free days. It responds to high 
PEEP and conservative fluid therapy.
(b) Hypo inflammatory type- It responds to low 
PEEP and liberal fluid therapy(25) .
Preliminary anecdotal reports on CARDS mentio-
ned(26)(27) that in the early phase of COVID-19, 
atypical ARDS features are more common (severe 
hypoxemia with high compliance and low lung 
recruitability) while in the later phase of disease, 
classic ARDS features are more common (low lung 
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specific, and at the discretion of the treating 
physician(19).
Ventilatory strategy for CARDS
The optimal time to intubate COVID-19 patients is 
still not clear. Mechanical ventilation should be 
considered if a COVID-19 patient develops 
moderate to severe ARDS (PaO /FiO  < 200) to 2 2
prevent P- SILI (Patient self-induced lung injury) 
and viral transmission to health care provider [6]. 
Endotracheal intubation and invasive mechanical 
ventilation are to be considered on priority in ARDS 
patients who are acutely deteriorating in spite of 
supplemental oxygen therapy with HFNC. Non-
intubated spontaneously breathing ARDS patients 
are at increased risk of P-SILI due to high intake of 
inhaled tidal volume. Therefore, oesophageal 
pressure measurement by manometer can be used 
in spontaneously breathing, non-intubated patients 
to estimate the time for intubation(20). The risk of 
infection to the HCW remains a concern. The 
oesophageal pressure between 5 to 10 cmH2o is 
generally well tolerated. However, if pressure goes 
more than 15 cmH2O, then risk of P-SILI increases 
and therefore intubation should be carried out as 
soon as possible. If oesophageal manometry is not 
available, then change in CVP (centre venous 
pressure) with respiration or clinical assessment of 
excessive inspiratory effort for increased work of 
breathing to be considered(21).
 
Mortality is very high (67%) for CARDS patients on 
mechanical ventilation (22). An inappropriate 
ventilatory strategy in ARDS patients can lead to 
VILI (Ventilator induced lung injury) which includes 
barotrauma (high airway pressure), volutrauma, 
atelectrauma, biotrauma, myotrauma (diaphrag-
matic injury) and oxytrauma (oxygen free radicles).
Non COVID -19 ARDS has two sub phenotypes 
identified based on the ARMA and ALVEOLI trial. 
They respond differently to PEEP, liberal fluid 
therapy and can be identified with notable precision 
using four biomarkers: interleukin-6, interferon 
gamma, angiopoietin 1/2, and plasminogen 
activator inhibitor-1 (23)(24)-
(a) Hyperinflammatory type- This type is 
associated with higher levels of inflammatory 
biomarkers, high vasopressor use, high sepsis, 
lower serum bicarbonate and have worst 
outcome in terms of mortality, ventilator free 
days and organ-free days. It responds to high 
PEEP and conservative fluid therapy.
(b) Hypo inflammatory type- It responds to low 
PEEP and liberal fluid therapy(25) .
Preliminary anecdotal reports on CARDS mentio-
ned(26)(27) that in the early phase of COVID-19, 
atypical ARDS features are more common (severe 
hypoxemia with high compliance and low lung 
recruitability) while in the later phase of disease, 
classic ARDS features are more common (low lung 
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compliance and high alveolar recruitability). 
Gattinoni et al.(26)(28) also reported that COVID-19 
pneumonia is of two types and their management 
varies in terms of ventilatory management –
a. Type L – characterised by low elastance, high 
compl iance, low lung weight,  low lung 
recruitability, and low ventilation-to perfusion 
(V/Q) ratio.
b. Type H- characterised by high elastance, low 
compliance, high lung weight, high lung 
recruitability, and high right-to-left shunt. This 
type of pneumonia has features like typical 
ARDS.
Currently there is no consensus on ventilatory 
management of CARDS patients. Hence, the 
ventilatory strategy for ARDS patients i/e low tidal 
volume ventilation, best suits for managing CARDS 
also. Salient features of the same are enumerated 
below:
(1) Lung protective ventilation(29)-
Several randomized control trials and meta-
analyses have reported survival benefits from low 
tidal volume lung protective ventilation. After 
implementation of low tidal volume ventilation in 
ARDS patients monitor auto-PEEP & ventilator 
dyssynchrony has to be monitored (30).  There is no 
single mode of ventilation which is markedly better 
than other modes in managing ARDS patients(31). 
However, most clinicians prefer to use volume-
limited assist-control mode for ventilating ARDS 
patients(30). Modes of ventilation like Airway 
pressure release ventilation (APRV) may be also be 
used based on physician's expertise(32). High 
frequency oscillatory ventilation is best avoided due 
to risk of aerosol spread and has shown no mortality 
benefit in ARDS patients(12). Even, Pressure-
regulated volume control is also not an accepted 
mode of ventilation in ARDS patients due to high 
tidal volume delivery surpassing the lung-protective 
ventilation target. The following initial ventilatory 
settings (Table 1) are recommended in COVID-19 
patients:
Serial No. Initial ventilator setting Remarks
1 Mode 
Volume-limited assist-control (monitor PIP, Pplat pressure, auto-
PEEP)
Tidal Volume setting should be based on predicted body weight 
and not on total body weight. 
Predicted body weight formula: 
Men: 50 + (0.91 × [height in centimetres − 152.4])  
Women: 45.5 + (0.91 × [height in centimetres − 152.4])
3
Respiratory rate <35/min, 
(start with15-20/min)
Adjust respiratory rate to maintain minute ventilation. However, 
permissive hypercapnia (pH >7.25) is allowed to prevent VILI.
4
Peak inspiratory flow (50-
60ltr/min)
Lower flow, specially when RR set > 20/min to increase 
inspiratory time and avoid barotrauma. The main purpose of this 
is to increase I: E ratio up to 1:1 to prevent barotrauma (Normal 
I: E ratio = 1:2).
5 FiO2 Start with 0.5 and titrate it based on arterial saturation. 
6
PEEP (start with 5-8 cm 
H2O)
Adjust PEEP based on FiO2 requirement and respiratory 




When NMBA and deep sedation is considered in severe 
refractory hypoxia, set trigger sensitivity at maximum to minimize 
risk of patient- ventilator interaction. 
8 Inspiratory pause
Adjust to 0.2 to 0.5 seconds. This helps to measure Pplat 
pressure, driving pressure and increase inspiratory time (to 
prevent barotrauma).
9 Flow pattern
Use constant flow when inspiratory time is normal (0.7 to 1 sec) 
otherwise, consider decelerating flow to prolong inspiratory time.
2
Tidal volume 6ml/kg (4-
8ml/kg)
Table 1 Ventilator settings for lung protective ventilation
(2) Role of PEEP in CARDS-
There is an ambiguity with optimal PEEP for 
CARDS patients. Using higher PEEP (any PEEP 
>10cm H2O) was not recommended based on the 
heterogenicity of lung involvement in COVID-19 
patients (with simultaneous existence of severely 
affected areas with non-affected areas in the lung).  
However, surviving sepsis campaign guidelines on 
management of critically ill adults from COVID-19, 
European intensive and critical care guidelines, 
advise PEEP > 10cm H2O for management of 
ARDS due to SARS-CoV-2. Titrations need to done 
by checking for lung compliance of COVID-19 
patients. If it is high or normal with presence of 
hypoxemia which is more common in L- Phenotype, 
then use of PEEP less than 10 cm H2O is 
recommended to avoid over-distention of normal 
healthy alveoli. However, if compliance is low, which 
is more common in H- Phenotype of COVID-19 
pneumonia likely also seen in ARDS, then use 
PEEP just above the lower inflection point on 
pressure volume loop on the ventilator to recruit 
collapsed alveoli, and prevent atelectasis and 
thereby, improve oxygenation. Monitor for alveolar 
over-distension by observing 'Beaking' pattern on 
pressure- volume loop which can be corrected 
either by decreasing tidal volume or PEEP (Figure 
1).
Figure 1 Pressure-Volume loop with lower inflection point
(3)  FiO /PEEP ladder for oxygenation - ARDSNet 2
trial (33) recommends to consider two types of 
FiO /PEEP ladder to achieve the goal of PaO  > 55 2 2
mm Hg in ARDS patients and to avoid the side 
effects of hyperoxia. D Trasy et al's study(34) 
recommends use of FiO /PEEP index ≤7 which is 2
similar to the ARDSNet trials of minimum 
FiO /PEEP settings (35%/5 cmH O). The details of 2 2
FiO /PEEP ladder are tabulated below in Table 2,3 -2
(a) Higher FiO2/Lower PEEP
Table 2 Higher FiO2/Lower PEEP
(b) Lower FiO2/higher PEEP
Table 3 Lower FiO2/Lower PEEP
FiO2 0.3 0.4 0.4 0.5 0.5 0.6 0.7 0.7 0.7 0.8 0.9 0.9 0.9 1
PEEP 5 5 8 8 10 10 10 12 14 14 14 16 18 18-24
FiO2 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.5 0.5 0.5-0.8 0.8 0.9 1 1
PEEP 5 8 10 12 14 14 16 16 18 20 22 22 22 24
Once the initial ventilator settings are entered, then 
the following parameters are monitored along with 
their target levels-
(a) Plateau pressure- Plateau pressure should be 
below 30 cm H O. It is defined as the pressure 2
that is maintained in the alveoli when there is no 
airflow. It is slightly lower than P  pressure and peak
is measured by adding an inspiratory pause of 
0.5 to 1 second on volume control mode 
showing pressure time scalar.
(b) Driving pressure- It is measured by formula : 
Driving pressure= (P  pressure – PEEP)plat
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compliance and high alveolar recruitability). 
Gattinoni et al.(26)(28) also reported that COVID-19 
pneumonia is of two types and their management 
varies in terms of ventilatory management –
a. Type L – characterised by low elastance, high 
compl iance, low lung weight,  low lung 
recruitability, and low ventilation-to perfusion 
(V/Q) ratio.
b. Type H- characterised by high elastance, low 
compliance, high lung weight, high lung 
recruitability, and high right-to-left shunt. This 
type of pneumonia has features like typical 
ARDS.
Currently there is no consensus on ventilatory 
management of CARDS patients. Hence, the 
ventilatory strategy for ARDS patients i/e low tidal 
volume ventilation, best suits for managing CARDS 
also. Salient features of the same are enumerated 
below:
(1) Lung protective ventilation(29)-
Several randomized control trials and meta-
analyses have reported survival benefits from low 
tidal volume lung protective ventilation. After 
implementation of low tidal volume ventilation in 
ARDS patients monitor auto-PEEP & ventilator 
dyssynchrony has to be monitored (30).  There is no 
single mode of ventilation which is markedly better 
than other modes in managing ARDS patients(31). 
However, most clinicians prefer to use volume-
limited assist-control mode for ventilating ARDS 
patients(30). Modes of ventilation like Airway 
pressure release ventilation (APRV) may be also be 
used based on physician's expertise(32). High 
frequency oscillatory ventilation is best avoided due 
to risk of aerosol spread and has shown no mortality 
benefit in ARDS patients(12). Even, Pressure-
regulated volume control is also not an accepted 
mode of ventilation in ARDS patients due to high 
tidal volume delivery surpassing the lung-protective 
ventilation target. The following initial ventilatory 
settings (Table 1) are recommended in COVID-19 
patients:
Serial No. Initial ventilator setting Remarks
1 Mode 
Volume-limited assist-control (monitor PIP, Pplat pressure, auto-
PEEP)
Tidal Volume setting should be based on predicted body weight 
and not on total body weight. 
Predicted body weight formula: 
Men: 50 + (0.91 × [height in centimetres − 152.4])  
Women: 45.5 + (0.91 × [height in centimetres − 152.4])
3
Respiratory rate <35/min, 
(start with15-20/min)
Adjust respiratory rate to maintain minute ventilation. However, 
permissive hypercapnia (pH >7.25) is allowed to prevent VILI.
4
Peak inspiratory flow (50-
60ltr/min)
Lower flow, specially when RR set > 20/min to increase 
inspiratory time and avoid barotrauma. The main purpose of this 
is to increase I: E ratio up to 1:1 to prevent barotrauma (Normal 
I: E ratio = 1:2).
5 FiO2 Start with 0.5 and titrate it based on arterial saturation. 
6
PEEP (start with 5-8 cm 
H2O)
Adjust PEEP based on FiO2 requirement and respiratory 




When NMBA and deep sedation is considered in severe 
refractory hypoxia, set trigger sensitivity at maximum to minimize 
risk of patient- ventilator interaction. 
8 Inspiratory pause
Adjust to 0.2 to 0.5 seconds. This helps to measure Pplat 
pressure, driving pressure and increase inspiratory time (to 
prevent barotrauma).
9 Flow pattern
Use constant flow when inspiratory time is normal (0.7 to 1 sec) 
otherwise, consider decelerating flow to prolong inspiratory time.
2
Tidal volume 6ml/kg (4-
8ml/kg)
Table 1 Ventilator settings for lung protective ventilation
(2) Role of PEEP in CARDS-
There is an ambiguity with optimal PEEP for 
CARDS patients. Using higher PEEP (any PEEP 
>10cm H2O) was not recommended based on the 
heterogenicity of lung involvement in COVID-19 
patients (with simultaneous existence of severely 
affected areas with non-affected areas in the lung).  
However, surviving sepsis campaign guidelines on 
management of critically ill adults from COVID-19, 
European intensive and critical care guidelines, 
advise PEEP > 10cm H2O for management of 
ARDS due to SARS-CoV-2. Titrations need to done 
by checking for lung compliance of COVID-19 
patients. If it is high or normal with presence of 
hypoxemia which is more common in L- Phenotype, 
then use of PEEP less than 10 cm H2O is 
recommended to avoid over-distention of normal 
healthy alveoli. However, if compliance is low, which 
is more common in H- Phenotype of COVID-19 
pneumonia likely also seen in ARDS, then use 
PEEP just above the lower inflection point on 
pressure volume loop on the ventilator to recruit 
collapsed alveoli, and prevent atelectasis and 
thereby, improve oxygenation. Monitor for alveolar 
over-distension by observing 'Beaking' pattern on 
pressure- volume loop which can be corrected 
either by decreasing tidal volume or PEEP (Figure 
1).
Figure 1 Pressure-Volume loop with lower inflection point
(3)  FiO /PEEP ladder for oxygenation - ARDSNet 2
trial (33) recommends to consider two types of 
FiO /PEEP ladder to achieve the goal of PaO  > 55 2 2
mm Hg in ARDS patients and to avoid the side 
effects of hyperoxia. D Trasy et al's study(34) 
recommends use of FiO /PEEP index ≤7 which is 2
similar to the ARDSNet trials of minimum 
FiO /PEEP settings (35%/5 cmH O). The details of 2 2
FiO /PEEP ladder are tabulated below in Table 2,3 -2
(a) Higher FiO2/Lower PEEP
Table 2 Higher FiO2/Lower PEEP
(b) Lower FiO2/higher PEEP
Table 3 Lower FiO2/Lower PEEP
FiO2 0.3 0.4 0.4 0.5 0.5 0.6 0.7 0.7 0.7 0.8 0.9 0.9 0.9 1
PEEP 5 5 8 8 10 10 10 12 14 14 14 16 18 18-24
FiO2 0.3 0.3 0.3 0.3 0.3 0.4 0.4 0.5 0.5 0.5-0.8 0.8 0.9 1 1
PEEP 5 8 10 12 14 14 16 16 18 20 22 22 22 24
Once the initial ventilator settings are entered, then 
the following parameters are monitored along with 
their target levels-
(a) Plateau pressure- Plateau pressure should be 
below 30 cm H O. It is defined as the pressure 2
that is maintained in the alveoli when there is no 
airflow. It is slightly lower than P  pressure and peak
is measured by adding an inspiratory pause of 
0.5 to 1 second on volume control mode 
showing pressure time scalar.
(b) Driving pressure- It is measured by formula : 
Driving pressure= (P  pressure – PEEP)plat
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This pressure should be below 15cm H O and is 2
achieved by either decreasing tidal volume (at 
the risk of development of hypercapnia) or by 
increasing PEEP (risk of overdistention of 
alveoli). Therefore, PEEP and tidal volume 
should be carefully titrated to keep driving 
pressure low.
(c) Compliance – It is a measure of ease of 
distensibility of lung elastic tissue. The easier a 
lung able to expand or stretch, more will be its 
compliance. Normally, the total compliance of 
both lungs in an adult is about 200 ml/ cm H O. 2
Low compliance is usually found in ARDS 
patients with stiff lung. There are two types of 
lung compliance-
1.Static compliance = Tidal volume
                                         P - PEEPplat
Static compliance measures pulmonary complian-
ce when no airflow such as during inspiratory pause 
and it is slightly higher than dynamic compliance.   
             
2. Dynamic compliance = Tidal volume
                                                 PIP - PEEP
It represents pulmonary compliance during active 
inspiration and depends upon peak inspiratory 
pressure (PIP). PIP depends on airway resistance. 
COVID -19 Pneumonia is a L phenotype(26)(28) 
usually with high compliance (> 40ml/cm H O). So, 2
a low PEEP and high tidal volume up to 8-9ml/kg (if 
hypercapnia present) is advised. H- phenotype 
pneumonia is managed like ARDS with lung 
protective ventilation (low tidal volume (4-6ml/kg) 
along with high PEEP). Therefore, it is essential to 
look for respiratory compliance of these patients 
prior to make any adjustment in ventilatory settings. 
(d) P0.1 (Airway occlusion pressure)- It is defined 
as the pressure generated in the airways during the 
first 100 msec of an inspiratory effort against an 
occluded airway. This can be measured in most 
modern ventilators. The normal value of P0.1 (in 
spontaneously breathing patients) is about 1 cm 
H O. However, in mechanically ventilated patients' 2
values above 3.5 cm H O are associated with 2
increased effort. Therefore, airway occlusion 
pressure value in CARDS patients should be kept 
less than 3.5 cm H O to obtain a ventilatory strategy 2
protective for the lung (to prevent it from VILI and 
diaphragmatic injury (Myotrauma)).
(3) Target goals of mechanical ventilation(35)-
1. Target SPO2 = 90-94%
2. PaO  > 55 mm Hg.2
3. pH > 7.25
4. FiO < 0.42 
5. PaO /FiO  > 300mm Hg.2 2
(4) Subsequent ventilatory settings- Subsequent 
ventilatory settings is decided by dynamic 
assessment of P  pressure, driving pressure, plat
compliance, and ABG (pH, oxygenation level) as 
done in non-CARDS(33). Some working guidelines 
are as under:
(a) If Pplat ≤30 cm H O, tidal volume (6 mL/kg) 2
and normal PH- No further adjustments.
(b) If Pplat >30 cm H O and tidal volume (6 2
mL/kg or higher) – Decrease tidal volume to 
5ml/kg if required, further decrease it to 4ml/kg. 
Consider increase in respiratory rate till up to 
35/min to maintain an acceptable minute 
ventilation.
(c) If ventilator dyssynchrony present with P  plat
<25 cm H O and tidal volume (<6 mL/kg)- 2
increase tidal volume to 1 mL/kg increments up to 
8ml/kg to achieve P >25 and ≤30 cm H O.plat 2
(d) If pH > 7.45 with respiratory alkalosis- 
decrease respiratory rate to target pH 7.25 -7.45.
(e) If pH < 7.25 with respiratory acidosis- 
increase respiratory rate up to 35/min (concern 
auto-PEEP) to target pH 7.25 -7.45.
(f) If pH < 7.15 with respiratory acidosis- after 
maximum respiratory rate (35/min), increase tidal 
volume in 1ml/kg increments (target P  < 30 cm plat
H O and PH 7.25 -7.45) or administer NaHCO  if 2 3
metabolic acidosis also present.
(5) Other adjuvant therapies:
(a) Sedation and analgesia
Propofol and midazolam are two most commonly 
used drugs for ICU sedation of mechanically 
ventilated patients and may be useful for sedation of 
CARDS patients who are on mechanical ventilation. 
Melatonin has been considered as a supportive 
therapy to improve sleep in COVID-19 patients in 
ICU, although more studies are required to validate 
this recommendation(36). In an ongoing pandemic 
like COVID-19, there is an acute shortage of 
sedatives and analgesics. Thus, some physi-
cians/intensivists have evaluated inhalational 
volatile anaesthestic agents as an alternative for 
sedation. Volatile anaesthetic agents like isoflurane 
& sevoflurane have advantages beyond sedation. 
This includes decreased airway resistance, 
bronchodilatation (in dose dependent manner), 
improved oxygenation, reduction of proinflam-
matory markers and decreased lung epithelial 
injury(37). However, they have not shown 
improvement in length of ICU stay or mortality 
benefit. Thus, further clinical studies or RCTs are 
required to interpret favourable outcome(38). To 
administer inhaled anaesthetics in ICU trained staff 
and anaesthesia machine / ventilator with miniature 
vaporizer and scavenging systems should be 
available. The main purpose of using sedation in 
COVID-19 patients with ARDS is to ensure patient 
comfort, alleviate anxiety, and to avoid ventilator 
asynchrony.
Two tools used to assess level of sedation in ICU 
patients are:
1. Richmond Agitation Sedation Scale (RASS)- A 
target of -3 to -4 points is kept for deep sedation of 
mechanically ventilated ICU patients. A target of -5 
is required when patients receive NMBA (to prevent 
patient- ventilator asynchrony) (39)(40).
2. Riker Sedation- Agitation Scale (SAS)- A target 
of 2 points is required to achieve deep sedation and 
SAS 1 is required for very deep sedation like 
patients on prone ventilation or ECMO. Light 
sedation by Dexmedetomidine with target value of 
SAS 3 - 4 may be suitable for COVID-19 patient on 
HFNC oxygen supplement therapy to control the 
physiological stress response(39).
In resource deficit conditions, processed EEG 
devices (Bispectral index (BIS), entropy and 
narcotrend-derived variables) can be utilized as a 
valuable monitoring device to reduce drug utili-
sation and to monitor need for sedatives (41)(42). 
Besides sedation, providing adequate analgesia is 
also equally important. A combination of agents 
(ketamine, fentanyl, morphine, hydromorphone, 
dexmedetomidine, remifentanil, sufentanil) may be 
considered as per requirement of the patient. 
According to PADIS guidelines(43), remifentanil 
and sufentanil are the analgesics of choice.
Three pain scoring scales are routinely used to 
assess the subjective nature of pain in ICU (39)-.
1. Numeric rating scale (NRS)- Target range < 4. 
This may be considered for non- ventilated 
spontaneously breathing COVID-19 patients who 
can express pain themselves.
2. Behavioral pain scale (BPS)- Target range < 5 
and can be used for mechanically ventilated 
patients.
3. Critical care pain observation tool (CPOT)- 
Target range < 3 and can be used in critically ill 
patients on invasive ventilation.
(b) NMBA (neuromuscular blocker agents)-
No clinical trials have been conducted on the use of 
NMBA in COVID-19 patients with ARDS. However, 
several intensive and critical care societies 
worldwide(44)(45) have made recommendations 
on the use of NMBA to improve oxygenation and to 
reduce ventilator dyssynchrony in ARDS patients. 
NMBA may be used in boluses (but not in 
continuous infusion) in moderate to severe ARDS 
patients with refractory hypoxemia (PaO / 2
FIO   <  120  mmHg) to facilitate oxygenation, 2
improved lung ventilation(46) and to avoid critical 
illness neuropathy. Routine use of neuromuscular 
blocking agents is not advised as it doesn`t reduce 
duration of mechanical ventilation and there is no 
survival benefit in ARDS patients. For intubation of 
CARDS patients, rapid sequence induction 
technique practiced, and therefore, succinylcholine 
and rocuronium are the preferred choice of NMBA in 
COVID-19 patients(10)(47). However, for inter-
mittent boluses, rocuronium, vecuronium, and 
atracurium are more preferred compared to 
succinylcholine. TOF monitoring in ICU can 
contribute to better utilisation of NMBA [31].
(c) Recruitment manoeuvres (Rms)-
Recruitment manoeuvres with high PEEP are used 
to improve oxygenation in CARDS patients by 
increasing transpulmonary pressure to open 
atelectatic or collapsed alveoli. Until now, no studies 
have found out the exact role of recruitment mano-
euvres (RMs) in patients with ARDS secondary to 
SARS-CoV-2. Surviving Sepsis Campaign 
guidelines(48)advise to use RMs with high PEEP to 
open collapsed alveoli and against the use of 
incremental PEEP titration RMs in COVID-19 
patients. Use of incremental PEEP for recruitment 
manoeuvres is discouraged in favour of RMs with 
high PEEP in COVID-19 patients. WHO interim 
guidelines also advise use of intermittent 
recruitment manoeuvres with high PEEP to improve 
oxygenation in ARDS due to COVID-19. It is 
essential to watch for hypotension, desaturation, 
and lung barotrauma during RMs. The two types of 
RMs used in ARDS patients are as under (48)-
1. Traditional RMs – High level of CPAP (35-40 cm 
H2O) along with prolonged inspiratory pause 
(40sec) is preferred in COVID-19 patients.
2. Incremental PEEP titration RMs- In this RM, 
incremental PEEP is used from 25 to 35 to 45 cm 
H20 for 1–2 min each and not recommended for 
COVID-19. 
(d) Administration of Steroids
WHO recommends(29) administration of steroids in 
CARDS patients on mechanical ventilator who have 
developed septic shock and require increasing 
dose of vasopressors to maintain MAP > 65 mm Hg. 
Inj. Hydrocortisone 200mg/day or prednisolone 
75mg/day is adviced. Surviving Sepsis Campaign 
guidelines(48) suggest use of systemic corticos-
teroids in CARDS and advise to use corticosteroids 
in lower doses for shorter duration. However, 
routine use of corticosteroids for COVID-19 
mechanically ventilated patients with respiratory 
insufficiency without ARDS is not recommended.
(e) Anti-Thrombotic therapy for CARDS
Antiplatelet therapy is associated with reduced 
mortality and lower incidence of ARDS/ALI in 
critically ill patients, particularly those with 
predisposing conditions such as high-risk surgery, 
trauma, pneumonia, and sepsis(49). Accordingly, it 
may act as a prophylactic agent and/or as a 
treatment in critically ill patients with the above 
mentioned conditions. Importantly, with a large 
number of the critically ill population, even a low rate 
of avoidable harm will be associated with massive 
preventable deaths. Consequently, it is imperative 
to identify the role of antiplatelet treatment as an 
adjunctive therapy in critically ill patients.
(f) Fluid therapy
WHO [19] and Surviving Sepsis Campaign 
guidelines(48) recommends use of conservative or 
restricted fluid therapy, over liberal fluid. It has 
shown to decrease the number of days on ventilator 
and shortens ICU stay. Surviving Sepsis Campaign 
guidelines used indirect evidence and recommends 
use of dynamic parameters (Skin temperature, 
capillary refill time, serum lactate, stroke volume 
variation (SVV), pulse pressure variation (PPV) and 
stroke volume change with passive leg raising) over 
119Invasive Mechanical Ventilation and COVID-19118 Singh V, Sasidharan S, Naseer A, Singh-Dhillon H, Manalikuzhiyil B, Singh S, Sinha D, Kaur-Dhillon G, Singh S
ISSN 2616 - 6097, Rev Peru Investig Salud, 2021, 5(2), : 113-126abril - junioISSN 2616 - 6097, Rev Peru Investig Salud, 2021, 5(2), : 113-126abril - junio
This pressure should be below 15cm H O and is 2
achieved by either decreasing tidal volume (at 
the risk of development of hypercapnia) or by 
increasing PEEP (risk of overdistention of 
alveoli). Therefore, PEEP and tidal volume 
should be carefully titrated to keep driving 
pressure low.
(c) Compliance – It is a measure of ease of 
distensibility of lung elastic tissue. The easier a 
lung able to expand or stretch, more will be its 
compliance. Normally, the total compliance of 
both lungs in an adult is about 200 ml/ cm H O. 2
Low compliance is usually found in ARDS 
patients with stiff lung. There are two types of 
lung compliance-
1.Static compliance = Tidal volume
                                         P - PEEPplat
Static compliance measures pulmonary complian-
ce when no airflow such as during inspiratory pause 
and it is slightly higher than dynamic compliance.   
             
2. Dynamic compliance = Tidal volume
                                                 PIP - PEEP
It represents pulmonary compliance during active 
inspiration and depends upon peak inspiratory 
pressure (PIP). PIP depends on airway resistance. 
COVID -19 Pneumonia is a L phenotype(26)(28) 
usually with high compliance (> 40ml/cm H O). So, 2
a low PEEP and high tidal volume up to 8-9ml/kg (if 
hypercapnia present) is advised. H- phenotype 
pneumonia is managed like ARDS with lung 
protective ventilation (low tidal volume (4-6ml/kg) 
along with high PEEP). Therefore, it is essential to 
look for respiratory compliance of these patients 
prior to make any adjustment in ventilatory settings. 
(d) P0.1 (Airway occlusion pressure)- It is defined 
as the pressure generated in the airways during the 
first 100 msec of an inspiratory effort against an 
occluded airway. This can be measured in most 
modern ventilators. The normal value of P0.1 (in 
spontaneously breathing patients) is about 1 cm 
H O. However, in mechanically ventilated patients' 2
values above 3.5 cm H O are associated with 2
increased effort. Therefore, airway occlusion 
pressure value in CARDS patients should be kept 
less than 3.5 cm H O to obtain a ventilatory strategy 2
protective for the lung (to prevent it from VILI and 
diaphragmatic injury (Myotrauma)).
(3) Target goals of mechanical ventilation(35)-
1. Target SPO2 = 90-94%
2. PaO  > 55 mm Hg.2
3. pH > 7.25
4. FiO < 0.42 
5. PaO /FiO  > 300mm Hg.2 2
(4) Subsequent ventilatory settings- Subsequent 
ventilatory settings is decided by dynamic 
assessment of P  pressure, driving pressure, plat
compliance, and ABG (pH, oxygenation level) as 
done in non-CARDS(33). Some working guidelines 
are as under:
(a) If Pplat ≤30 cm H O, tidal volume (6 mL/kg) 2
and normal PH- No further adjustments.
(b) If Pplat >30 cm H O and tidal volume (6 2
mL/kg or higher) – Decrease tidal volume to 
5ml/kg if required, further decrease it to 4ml/kg. 
Consider increase in respiratory rate till up to 
35/min to maintain an acceptable minute 
ventilation.
(c) If ventilator dyssynchrony present with P  plat
<25 cm H O and tidal volume (<6 mL/kg)- 2
increase tidal volume to 1 mL/kg increments up to 
8ml/kg to achieve P >25 and ≤30 cm H O.plat 2
(d) If pH > 7.45 with respiratory alkalosis- 
decrease respiratory rate to target pH 7.25 -7.45.
(e) If pH < 7.25 with respiratory acidosis- 
increase respiratory rate up to 35/min (concern 
auto-PEEP) to target pH 7.25 -7.45.
(f) If pH < 7.15 with respiratory acidosis- after 
maximum respiratory rate (35/min), increase tidal 
volume in 1ml/kg increments (target P  < 30 cm plat
H O and PH 7.25 -7.45) or administer NaHCO  if 2 3
metabolic acidosis also present.
(5) Other adjuvant therapies:
(a) Sedation and analgesia
Propofol and midazolam are two most commonly 
used drugs for ICU sedation of mechanically 
ventilated patients and may be useful for sedation of 
CARDS patients who are on mechanical ventilation. 
Melatonin has been considered as a supportive 
therapy to improve sleep in COVID-19 patients in 
ICU, although more studies are required to validate 
this recommendation(36). In an ongoing pandemic 
like COVID-19, there is an acute shortage of 
sedatives and analgesics. Thus, some physi-
cians/intensivists have evaluated inhalational 
volatile anaesthestic agents as an alternative for 
sedation. Volatile anaesthetic agents like isoflurane 
& sevoflurane have advantages beyond sedation. 
This includes decreased airway resistance, 
bronchodilatation (in dose dependent manner), 
improved oxygenation, reduction of proinflam-
matory markers and decreased lung epithelial 
injury(37). However, they have not shown 
improvement in length of ICU stay or mortality 
benefit. Thus, further clinical studies or RCTs are 
required to interpret favourable outcome(38). To 
administer inhaled anaesthetics in ICU trained staff 
and anaesthesia machine / ventilator with miniature 
vaporizer and scavenging systems should be 
available. The main purpose of using sedation in 
COVID-19 patients with ARDS is to ensure patient 
comfort, alleviate anxiety, and to avoid ventilator 
asynchrony.
Two tools used to assess level of sedation in ICU 
patients are:
1. Richmond Agitation Sedation Scale (RASS)- A 
target of -3 to -4 points is kept for deep sedation of 
mechanically ventilated ICU patients. A target of -5 
is required when patients receive NMBA (to prevent 
patient- ventilator asynchrony) (39)(40).
2. Riker Sedation- Agitation Scale (SAS)- A target 
of 2 points is required to achieve deep sedation and 
SAS 1 is required for very deep sedation like 
patients on prone ventilation or ECMO. Light 
sedation by Dexmedetomidine with target value of 
SAS 3 - 4 may be suitable for COVID-19 patient on 
HFNC oxygen supplement therapy to control the 
physiological stress response(39).
In resource deficit conditions, processed EEG 
devices (Bispectral index (BIS), entropy and 
narcotrend-derived variables) can be utilized as a 
valuable monitoring device to reduce drug utili-
sation and to monitor need for sedatives (41)(42). 
Besides sedation, providing adequate analgesia is 
also equally important. A combination of agents 
(ketamine, fentanyl, morphine, hydromorphone, 
dexmedetomidine, remifentanil, sufentanil) may be 
considered as per requirement of the patient. 
According to PADIS guidelines(43), remifentanil 
and sufentanil are the analgesics of choice.
Three pain scoring scales are routinely used to 
assess the subjective nature of pain in ICU (39)-.
1. Numeric rating scale (NRS)- Target range < 4. 
This may be considered for non- ventilated 
spontaneously breathing COVID-19 patients who 
can express pain themselves.
2. Behavioral pain scale (BPS)- Target range < 5 
and can be used for mechanically ventilated 
patients.
3. Critical care pain observation tool (CPOT)- 
Target range < 3 and can be used in critically ill 
patients on invasive ventilation.
(b) NMBA (neuromuscular blocker agents)-
No clinical trials have been conducted on the use of 
NMBA in COVID-19 patients with ARDS. However, 
several intensive and critical care societies 
worldwide(44)(45) have made recommendations 
on the use of NMBA to improve oxygenation and to 
reduce ventilator dyssynchrony in ARDS patients. 
NMBA may be used in boluses (but not in 
continuous infusion) in moderate to severe ARDS 
patients with refractory hypoxemia (PaO / 2
FIO   <  120  mmHg) to facilitate oxygenation, 2
improved lung ventilation(46) and to avoid critical 
illness neuropathy. Routine use of neuromuscular 
blocking agents is not advised as it doesn`t reduce 
duration of mechanical ventilation and there is no 
survival benefit in ARDS patients. For intubation of 
CARDS patients, rapid sequence induction 
technique practiced, and therefore, succinylcholine 
and rocuronium are the preferred choice of NMBA in 
COVID-19 patients(10)(47). However, for inter-
mittent boluses, rocuronium, vecuronium, and 
atracurium are more preferred compared to 
succinylcholine. TOF monitoring in ICU can 
contribute to better utilisation of NMBA [31].
(c) Recruitment manoeuvres (Rms)-
Recruitment manoeuvres with high PEEP are used 
to improve oxygenation in CARDS patients by 
increasing transpulmonary pressure to open 
atelectatic or collapsed alveoli. Until now, no studies 
have found out the exact role of recruitment mano-
euvres (RMs) in patients with ARDS secondary to 
SARS-CoV-2. Surviving Sepsis Campaign 
guidelines(48)advise to use RMs with high PEEP to 
open collapsed alveoli and against the use of 
incremental PEEP titration RMs in COVID-19 
patients. Use of incremental PEEP for recruitment 
manoeuvres is discouraged in favour of RMs with 
high PEEP in COVID-19 patients. WHO interim 
guidelines also advise use of intermittent 
recruitment manoeuvres with high PEEP to improve 
oxygenation in ARDS due to COVID-19. It is 
essential to watch for hypotension, desaturation, 
and lung barotrauma during RMs. The two types of 
RMs used in ARDS patients are as under (48)-
1. Traditional RMs – High level of CPAP (35-40 cm 
H2O) along with prolonged inspiratory pause 
(40sec) is preferred in COVID-19 patients.
2. Incremental PEEP titration RMs- In this RM, 
incremental PEEP is used from 25 to 35 to 45 cm 
H20 for 1–2 min each and not recommended for 
COVID-19. 
(d) Administration of Steroids
WHO recommends(29) administration of steroids in 
CARDS patients on mechanical ventilator who have 
developed septic shock and require increasing 
dose of vasopressors to maintain MAP > 65 mm Hg. 
Inj. Hydrocortisone 200mg/day or prednisolone 
75mg/day is adviced. Surviving Sepsis Campaign 
guidelines(48) suggest use of systemic corticos-
teroids in CARDS and advise to use corticosteroids 
in lower doses for shorter duration. However, 
routine use of corticosteroids for COVID-19 
mechanically ventilated patients with respiratory 
insufficiency without ARDS is not recommended.
(e) Anti-Thrombotic therapy for CARDS
Antiplatelet therapy is associated with reduced 
mortality and lower incidence of ARDS/ALI in 
critically ill patients, particularly those with 
predisposing conditions such as high-risk surgery, 
trauma, pneumonia, and sepsis(49). Accordingly, it 
may act as a prophylactic agent and/or as a 
treatment in critically ill patients with the above 
mentioned conditions. Importantly, with a large 
number of the critically ill population, even a low rate 
of avoidable harm will be associated with massive 
preventable deaths. Consequently, it is imperative 
to identify the role of antiplatelet treatment as an 
adjunctive therapy in critically ill patients.
(f) Fluid therapy
WHO [19] and Surviving Sepsis Campaign 
guidelines(48) recommends use of conservative or 
restricted fluid therapy, over liberal fluid. It has 
shown to decrease the number of days on ventilator 
and shortens ICU stay. Surviving Sepsis Campaign 
guidelines used indirect evidence and recommends 
use of dynamic parameters (Skin temperature, 
capillary refill time, serum lactate, stroke volume 
variation (SVV), pulse pressure variation (PPV) and 
stroke volume change with passive leg raising) over 
119Invasive Mechanical Ventilation and COVID-19118 Singh V, Sasidharan S, Naseer A, Singh-Dhillon H, Manalikuzhiyil B, Singh S, Sinha D, Kaur-Dhillon G, Singh S
ISSN 2616 - 6097, Rev Peru Investig Salud, 2021, 5(2), : 113-126abril - junioISSN 2616 - 6097, Rev Peru Investig Salud, 2021, 5(2), : 113-126abril - junio
static parameters (CVP) to assess fluid respon-
siveness in COVID-19 patients with septic shock.
(g) Nutritional support
According to ESPEN expert statements(50) and 
ESPEN guidelines(51), the nutritional support for 
SARS CoV-2 infected patients in ICU are as under-
1. Malnutrition assessment in polymorbid 
patients- MUST criteria & NRS criteria must be 
used to check/screen individuals with COVID-19 
for malnutrition . 
2. Patients on NIV- Peripheral parenteral nutrition 
is preferred as NIV along with enteral feed is 
associated with complications like stomach 
dilatation (prone for aspiration) and ineffective 
ventilation though due to air leak from the side of 
the facemask.
3. For patients on HFNC - Oral nutritional 
supplements can be after assessing the 
nutritional status of COVID-19 patient or start 
enteral feed if oral feed is not possible. 
4. Patients on ventilator –
a) Early enteral feed (within 48hrs of ICU 
admission) through nasogastric tube is 
favoured over late enteral and early parenteral 
feed.
b) Post pyloric feed to be started in patients prone 
for gastric aspiration or in cases of gastric 
intolerance after prokinetic drugs. 
c) Parenteral nutrition can be administered within 
3-7 days if contraindications to enteral nutrition 
are present.
d) Indirect calorimetry, VO2 or VCO2 estimation 
is recommended to guide daily energy 
expenditure (EE). If not available, weight-
based equations to be used to estimate daily 
calorie expenditure (20–25 kcal/kg/day)
e) Enteral nutrition can be given to prone 
ventilated patients and is verified to be safe in 
CARDS.
f) In the early phase of illness (first week), 
hypocaloric nutrition (not exceeding 70% of 
EE) should be administered. 
g) After the early phase of acute illness, isocaloric 
nutrition is recommended over hypocaloric 
nutrition. 
h) In frail patients, protein administration (1.3 g/kg 
/day) can be considered progressively during 
critical illness.
i) For obese patients, requirement of protein is 
1.3g/kg (adjusted body weight)/day. Adjusted 
body weight = Ideal body weight + 0.33 X 
(actual body weight - ideal body weight) 
j) EN can be delayed in haemodynamic unstable 
patients with shock on vasopressors, severe 
hypoxemia, and severe acidosis.
5. Post-extubation patients- Texture adapted food 
to be considered orally and if dysphagia is 
present (which is most common in post-
extubation), administer enteral nutrition.
(h) Management of septic shock
In the absence of direct evidence on COVID-19 
patients and septic shock, WHO interim guide-
lines(29) and Surviving Sepsis Campaign 
guidelines (48) recommends use of crystalloid 
intravenous balanced fluids like Normal Saline, 
Ringer`s Lactate as fluid bolus (1liter over 30min or 
faster) for septic shock to check for fluid respon-
siveness. Hypotonic fluids, colloids, hydroxyethyl 
starches, gelatin, dextrans and albumin should be 
avoided for resuscitation. If there is no fluid 
response and signs of fluid overload appear like 
crackles on auscultation, then discontinue the fluid 
and consider using vasopressors. In vasopressors, 
Norepinephrine is the drug of choice followed by 
vasopressin & adrenaline. Goal is to maintain MAP 
> 65mm Hg. Consider dobutamine in shock with 
evidence of cardiac dysfunction associated with 
persistent tissue hypoperfusion. Surviving Sepsis 
Campaign guidelines(48) doesn`t recommend 
dopamine in COVID-19 with shock possibly due to 
an increase risk of arrhythmias and lack of evidence 
of mortality benefit. These vasopressors should be 
titrated strictly to targeted blood pressure to 
maintain tissue perfusion and given preferably 
through a central venous catheter. When peripheral 
lines are used for infusion, watch for necrosis of skin 
or extravasation of vasopressors.
(6) Prone ventilation-
If lung protective ventilation fails to maintain 
adequate oxygenation (PaO2/FiO2 < 150mm Hg 
despite PEEP >5 and FiO2 > 0.6), then prone 
ventilation should be considered. Guérin et al 
PROSEVA trial(53) reports promising results in 
patients with severe ARDS. It is a well-known fact 
that prone ventilation along with early NMB agents 
has improved survivability in ARDS(23).  Prone 
ventilation also enhances oxygenation and 
decreases V/Q mismatch in ARDS patients. In 
COVID-19 patients' good response to prone 
positioning may be due to their well-preserved lung 
compliance compared with patients who develop 
ARDS from other causes. Therefore, patients are 
ventilated in prone position for at least 16 hours per 
day if patient fail to maintain oxygenation in supine 
position. However, utmost due care should be taken 
to avoid ventilator disconnections during position 
change, minimum staff should be kept for turning 
the patient to prone. Contraindications to prone 
ventilation (cervical spine injury, open chest, 
unstable airway, raised ICP, raised intraabdominal 
pressure) should be addressed prior to proning. It is 
imperative to mention that these patients should be 
well sedated to tolerate the tube and boluses of 
neuromuscular agents should be considered to 
avoid unnecessary coughing while turning to prone 
position. The optimal time and criteria to 
discontinue prone ventilation when PaO2/FiO2 
>150mm Hg with FiO2 < 0.6 and PEEP < 10 cm 
H2O for at least 4 hours in supine position after a 
trial of prone position(54).
(7) Role of pulmonary vasodilators-
The two most commonly used vasodilators in 
mechanically ventilated patients are inhaled nitric 
oxide gas (iNO) and epoprostenol. They are 
administered by continuous inhalation. Rescue 
therapy with them are considered to improve 
oxygenation when PaO2/FiO2 <100mm Hg despite 
prone ventilation or if it is associated with acute 
pulmonary arterial hypertension(48). If there is no 
improvement in oxygenation after instituting inhaled 
pulmonary vasodilators, then it should be tapered 
off without undue delay to avoid rebound pulmonary 
vasoconstriction. Epoprostenol has mild antipla-
telet action, so it should be avoided in alveolar 
haemorrhage. The risk of aerosolization and 
clogging of HME filters is particularly more with 
Epoprostenol and it remains a concern in COVID-
19 patients. That is why iNO is more preferred due 
to less frequent chance of filters and less risk of 
acquired infection in the HCWs. Routine use of 
inhaled nitric oxide in CARDS patients is not 
recommended as there is no evidence of survival 
benefit(48).
(8) Role of ECMO-
If oxygenation doesn`t improve and hypoxia still 
persists then VV-ECMO (veno-venous extracor-
poreal membrane oxygenation) can be considered 
subject to availability.
Indications of ECMO in COVID-19(55)-
(a) PaO /FiO  >150 but pH <7.25 with PaCO  >60 2 2 2
for more than 6 hours.
(b) PaO /FiO  <80 mm Hg for 6 hours, PaO2/FiO2 2 2
<50 mm Hg for 3 hrs, and other adjunctive 
measures fail (prone position, NMB, recruitment 
manoeuvres, inhaled pulmonary vasodilators).
ECMO is expensive and extremely resource-limited 
treatment requiring trained personnel. Therefore, 
its use as rescue therapy should be considered only 
in refractory hypoxic respiratory failure(56). So far, 
no RCTs or meta-analyses have been conducted on 
ECMO in CARDS. Few reports from China mention 
ECMO instituted for CARDS, but their course of 
hospital stay, clinical course, and outcome were not 
discussed(57).
(9) Ventilator Weaning and extubation of 
CARDS patients-
Special attention to avoid viral transmission to the 
health care providers during extubation in 
mandatory. Extubation is an aerosol generating 
procedure, so a high threshold for extubation 
should be kept for these patients to avoid 
unnecessary reintubation. Some physicians use 
cuff leak test criteria along with spontaneous 
breathing trials (SBT) to assess the readiness for 
weaning from mechanical ventilation on the 
assumption that these patients could have 
developed airway oedema due to prolonged 
ventilation. Since the risk of aerosol generation in 
cuff leak test is similar to extubation, it is advised to 
perform SAT (Spontaneous awakening trial) and 
SBT without T-piece at lower pressure support (0-
3cm H2O) along with use steroids prior to 
extubation. The following weaning criteria is 
recommended prior to extubation(58)-
1. Patient should be conscious, comfortable, and 
oriented.
2. PaO /FiO  > 300 mm Hg with PEEP < 5 cm H O.2 2 2
3. Hemodynamically stable and maintaining SPO  2
with FiO  < 0.4. 2
4. RSBI (Rapid shallow breathing index) < 105 – 
calculated by respiratory rate/tidal volume in 
litres when the intubated patient is breathing 
spontaneously
5. No signs of increase work of breathing or 
respiratory distress like use of accessory muscle, 
paradoxical or asynchronous respiration, nasal 
flaring, profuse diaphoresis, agitation, tachy-
pnoea, tachycardia or cyanosis. 
6. Good cough reflex with absence of expecto-
ration/secretion.
Appendix 1 provides an algorithm for management 
of a patient with CARDS.
(10) Prevention of complications-
Complications or adverse/side effects of mecha-
nical ventilation should be prevented in all cases of 
CARDS, as with any other case of ARDS. Few of the 
interventions are enumerated below:
(a) Prevention of Ventilator Associated Pneumonia 
(VAP) (59)  – 
     VAP can be prevented by following:
1. Spontaneous awakening and spontaneous 
breathing trails.
2. Head of bed elevation.
3. Selective digestive decontamination.
4. Thromboprophylaxis 
5. Oral care without chlorhexidine as some 
patients develops ARDS due to aspiration of 
chlorhexidine.
6. Use a new ventilator circuit for each patient.
7. Change HMEs filter when soiled.
8. Oral intubation preferred compare to nasal 
intubation.
(b) Reduce pressure sores and ulcers by frequent 
change of position every 2 hourly.
(c) Reduce stress ulcer, gastric bleeding by early 
enteral feeding within 24-48 hrs of ICU 
admission and consider PPI or H2 blocker.
(d) Reduce ICU related weakness by early 
mobilisation. 
(e) Reduce catheter related infection by using 
sterile aseptic technique while insertion and 
consider removal when not needed.
(f) Reduce the number of days on mechanical 
ventilation by daily assessment for readiness of 
extubation through spontaneous breathing 
trials.
(g) Reduce the incidence of venous thromboem-
bolism by use of pharmacological agents or 
mechanical compression devices.
(h) Suctioning of mechanically ventilated patients 
should be done with closed inline suction 
catheters to prevent aerosol spread and 
unnecessary ventilator disconnection should be 
avoided to prevent alveolar recruitment (32).
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static parameters (CVP) to assess fluid respon-
siveness in COVID-19 patients with septic shock.
(g) Nutritional support
According to ESPEN expert statements(50) and 
ESPEN guidelines(51), the nutritional support for 
SARS CoV-2 infected patients in ICU are as under-
1. Malnutrition assessment in polymorbid 
patients- MUST criteria & NRS criteria must be 
used to check/screen individuals with COVID-19 
for malnutrition . 
2. Patients on NIV- Peripheral parenteral nutrition 
is preferred as NIV along with enteral feed is 
associated with complications like stomach 
dilatation (prone for aspiration) and ineffective 
ventilation though due to air leak from the side of 
the facemask.
3. For patients on HFNC - Oral nutritional 
supplements can be after assessing the 
nutritional status of COVID-19 patient or start 
enteral feed if oral feed is not possible. 
4. Patients on ventilator –
a) Early enteral feed (within 48hrs of ICU 
admission) through nasogastric tube is 
favoured over late enteral and early parenteral 
feed.
b) Post pyloric feed to be started in patients prone 
for gastric aspiration or in cases of gastric 
intolerance after prokinetic drugs. 
c) Parenteral nutrition can be administered within 
3-7 days if contraindications to enteral nutrition 
are present.
d) Indirect calorimetry, VO2 or VCO2 estimation 
is recommended to guide daily energy 
expenditure (EE). If not available, weight-
based equations to be used to estimate daily 
calorie expenditure (20–25 kcal/kg/day)
e) Enteral nutrition can be given to prone 
ventilated patients and is verified to be safe in 
CARDS.
f) In the early phase of illness (first week), 
hypocaloric nutrition (not exceeding 70% of 
EE) should be administered. 
g) After the early phase of acute illness, isocaloric 
nutrition is recommended over hypocaloric 
nutrition. 
h) In frail patients, protein administration (1.3 g/kg 
/day) can be considered progressively during 
critical illness.
i) For obese patients, requirement of protein is 
1.3g/kg (adjusted body weight)/day. Adjusted 
body weight = Ideal body weight + 0.33 X 
(actual body weight - ideal body weight) 
j) EN can be delayed in haemodynamic unstable 
patients with shock on vasopressors, severe 
hypoxemia, and severe acidosis.
5. Post-extubation patients- Texture adapted food 
to be considered orally and if dysphagia is 
present (which is most common in post-
extubation), administer enteral nutrition.
(h) Management of septic shock
In the absence of direct evidence on COVID-19 
patients and septic shock, WHO interim guide-
lines(29) and Surviving Sepsis Campaign 
guidelines (48) recommends use of crystalloid 
intravenous balanced fluids like Normal Saline, 
Ringer`s Lactate as fluid bolus (1liter over 30min or 
faster) for septic shock to check for fluid respon-
siveness. Hypotonic fluids, colloids, hydroxyethyl 
starches, gelatin, dextrans and albumin should be 
avoided for resuscitation. If there is no fluid 
response and signs of fluid overload appear like 
crackles on auscultation, then discontinue the fluid 
and consider using vasopressors. In vasopressors, 
Norepinephrine is the drug of choice followed by 
vasopressin & adrenaline. Goal is to maintain MAP 
> 65mm Hg. Consider dobutamine in shock with 
evidence of cardiac dysfunction associated with 
persistent tissue hypoperfusion. Surviving Sepsis 
Campaign guidelines(48) doesn`t recommend 
dopamine in COVID-19 with shock possibly due to 
an increase risk of arrhythmias and lack of evidence 
of mortality benefit. These vasopressors should be 
titrated strictly to targeted blood pressure to 
maintain tissue perfusion and given preferably 
through a central venous catheter. When peripheral 
lines are used for infusion, watch for necrosis of skin 
or extravasation of vasopressors.
(6) Prone ventilation-
If lung protective ventilation fails to maintain 
adequate oxygenation (PaO2/FiO2 < 150mm Hg 
despite PEEP >5 and FiO2 > 0.6), then prone 
ventilation should be considered. Guérin et al 
PROSEVA trial(53) reports promising results in 
patients with severe ARDS. It is a well-known fact 
that prone ventilation along with early NMB agents 
has improved survivability in ARDS(23).  Prone 
ventilation also enhances oxygenation and 
decreases V/Q mismatch in ARDS patients. In 
COVID-19 patients' good response to prone 
positioning may be due to their well-preserved lung 
compliance compared with patients who develop 
ARDS from other causes. Therefore, patients are 
ventilated in prone position for at least 16 hours per 
day if patient fail to maintain oxygenation in supine 
position. However, utmost due care should be taken 
to avoid ventilator disconnections during position 
change, minimum staff should be kept for turning 
the patient to prone. Contraindications to prone 
ventilation (cervical spine injury, open chest, 
unstable airway, raised ICP, raised intraabdominal 
pressure) should be addressed prior to proning. It is 
imperative to mention that these patients should be 
well sedated to tolerate the tube and boluses of 
neuromuscular agents should be considered to 
avoid unnecessary coughing while turning to prone 
position. The optimal time and criteria to 
discontinue prone ventilation when PaO2/FiO2 
>150mm Hg with FiO2 < 0.6 and PEEP < 10 cm 
H2O for at least 4 hours in supine position after a 
trial of prone position(54).
(7) Role of pulmonary vasodilators-
The two most commonly used vasodilators in 
mechanically ventilated patients are inhaled nitric 
oxide gas (iNO) and epoprostenol. They are 
administered by continuous inhalation. Rescue 
therapy with them are considered to improve 
oxygenation when PaO2/FiO2 <100mm Hg despite 
prone ventilation or if it is associated with acute 
pulmonary arterial hypertension(48). If there is no 
improvement in oxygenation after instituting inhaled 
pulmonary vasodilators, then it should be tapered 
off without undue delay to avoid rebound pulmonary 
vasoconstriction. Epoprostenol has mild antipla-
telet action, so it should be avoided in alveolar 
haemorrhage. The risk of aerosolization and 
clogging of HME filters is particularly more with 
Epoprostenol and it remains a concern in COVID-
19 patients. That is why iNO is more preferred due 
to less frequent chance of filters and less risk of 
acquired infection in the HCWs. Routine use of 
inhaled nitric oxide in CARDS patients is not 
recommended as there is no evidence of survival 
benefit(48).
(8) Role of ECMO-
If oxygenation doesn`t improve and hypoxia still 
persists then VV-ECMO (veno-venous extracor-
poreal membrane oxygenation) can be considered 
subject to availability.
Indications of ECMO in COVID-19(55)-
(a) PaO /FiO  >150 but pH <7.25 with PaCO  >60 2 2 2
for more than 6 hours.
(b) PaO /FiO  <80 mm Hg for 6 hours, PaO2/FiO2 2 2
<50 mm Hg for 3 hrs, and other adjunctive 
measures fail (prone position, NMB, recruitment 
manoeuvres, inhaled pulmonary vasodilators).
ECMO is expensive and extremely resource-limited 
treatment requiring trained personnel. Therefore, 
its use as rescue therapy should be considered only 
in refractory hypoxic respiratory failure(56). So far, 
no RCTs or meta-analyses have been conducted on 
ECMO in CARDS. Few reports from China mention 
ECMO instituted for CARDS, but their course of 
hospital stay, clinical course, and outcome were not 
discussed(57).
(9) Ventilator Weaning and extubation of 
CARDS patients-
Special attention to avoid viral transmission to the 
health care providers during extubation in 
mandatory. Extubation is an aerosol generating 
procedure, so a high threshold for extubation 
should be kept for these patients to avoid 
unnecessary reintubation. Some physicians use 
cuff leak test criteria along with spontaneous 
breathing trials (SBT) to assess the readiness for 
weaning from mechanical ventilation on the 
assumption that these patients could have 
developed airway oedema due to prolonged 
ventilation. Since the risk of aerosol generation in 
cuff leak test is similar to extubation, it is advised to 
perform SAT (Spontaneous awakening trial) and 
SBT without T-piece at lower pressure support (0-
3cm H2O) along with use steroids prior to 
extubation. The following weaning criteria is 
recommended prior to extubation(58)-
1. Patient should be conscious, comfortable, and 
oriented.
2. PaO /FiO  > 300 mm Hg with PEEP < 5 cm H O.2 2 2
3. Hemodynamically stable and maintaining SPO  2
with FiO  < 0.4. 2
4. RSBI (Rapid shallow breathing index) < 105 – 
calculated by respiratory rate/tidal volume in 
litres when the intubated patient is breathing 
spontaneously
5. No signs of increase work of breathing or 
respiratory distress like use of accessory muscle, 
paradoxical or asynchronous respiration, nasal 
flaring, profuse diaphoresis, agitation, tachy-
pnoea, tachycardia or cyanosis. 
6. Good cough reflex with absence of expecto-
ration/secretion.
Appendix 1 provides an algorithm for management 
of a patient with CARDS.
(10) Prevention of complications-
Complications or adverse/side effects of mecha-
nical ventilation should be prevented in all cases of 
CARDS, as with any other case of ARDS. Few of the 
interventions are enumerated below:
(a) Prevention of Ventilator Associated Pneumonia 
(VAP) (59)  – 
     VAP can be prevented by following:
1. Spontaneous awakening and spontaneous 
breathing trails.
2. Head of bed elevation.
3. Selective digestive decontamination.
4. Thromboprophylaxis 
5. Oral care without chlorhexidine as some 
patients develops ARDS due to aspiration of 
chlorhexidine.
6. Use a new ventilator circuit for each patient.
7. Change HMEs filter when soiled.
8. Oral intubation preferred compare to nasal 
intubation.
(b) Reduce pressure sores and ulcers by frequent 
change of position every 2 hourly.
(c) Reduce stress ulcer, gastric bleeding by early 
enteral feeding within 24-48 hrs of ICU 
admission and consider PPI or H2 blocker.
(d) Reduce ICU related weakness by early 
mobilisation. 
(e) Reduce catheter related infection by using 
sterile aseptic technique while insertion and 
consider removal when not needed.
(f) Reduce the number of days on mechanical 
ventilation by daily assessment for readiness of 
extubation through spontaneous breathing 
trials.
(g) Reduce the incidence of venous thromboem-
bolism by use of pharmacological agents or 
mechanical compression devices.
(h) Suctioning of mechanically ventilated patients 
should be done with closed inline suction 
catheters to prevent aerosol spread and 
unnecessary ventilator disconnection should be 
avoided to prevent alveolar recruitment (32).
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(11) Understanding recent advances in ARDS 
treatment-
Salient features from various RCTs and clinical 
trials, that reflect recent advances and consensus in 
the understanding and management of ARDS-
(a) Multiple trials(60)(61) have failed to confirm the 
benefit of using recruitment manoeuvres in 
ARDS patients.
(b) The LUNG-SAFE study(23)(62) - Shown 
increased mortality with noninvasive ventilation 
in severe ARDS patients. 
(c) Liberal oxygen or conservative oxygen 
(LOCO ) trial(63)- Conservative oxygenation 2
strategy did not reveal increased survival 
benefits. So, hyperoxia (SpO2 >97%) and 
hypoxemia (SpO2 <90%) should be avoided.
(d) SUPERNOVA study(64)- Use of extracorporeal 
carbon dioxide removal can be utilized to enable 
ultra-protective ventilation (Tidal volume= 4 
mL/kg and P  ≤ 25 cmH O) in ARDS.PLAT 2
(e) EOLIA trial(65)- Fails to approve the superiority 
of routine use of ECMO therapy in severe ARDS 
over rescue ECMO therapy.
For the transport of intubated patients, the use of 
evacuation pods have also been described for a 
medical evacuation (66).
Neuropsychiatric symptoms in cards
Long-term outcomes of patients with ARDS are 
being increasingly recognized as important 
research targets, as many patients survive ARDS 
only to have ongoing functional and/or psycholo-
gical sequelae.
The etiopathogenesis of neuropsychiatric manifes-
tations could be either due to primary neuro-
invasion by the coronavirus 2 (SARS-CoV-2) or a 
secondary attack of inflammation by activated 
immune and inflammatory mediators. The most 
common psychiatric presentation in ICU is of 
Delirium but other neurological symptoms such as 
rigidity, myoclonus, catatonia can also be encoun-
tered.
Delirium- The prevalence of delirium in intubated 
patients is up to 80%(67) which is further 
exacerbated in CARDS patient. The risk factors 
include old age (>65yrs), medical co-morbidity, 
drugs (propofol, opiods, and high-dose benzo-
diazepines, which are routinely used during 
mechanical ventilation), hydroxychloroquine 
(67,68).
Delirium can be objectively assessed and 
monitored with 'Confusion Assessment Method for 
the ICU' scale(69).
The management comprises of:
1. Regularizing the sleep cycle
Melatonin should be used for regularizing sleep-
wake cycle in delirium owing to its short half-life, 
additional mild anti-inflammatory properties and 
no respiratory depression (69).
Benzodiazepines should be avoided (except in 
cases of delirium tremens), as cumulative doses 
run the risk of respiratory depression and may 
cause paradoxical disinhibition. Zolpidem (2.5-
5mg) is relatively safer in terms of respiratory 
functioning, but levels are increased in patients 
taking ritonavir.
2. Acute agitation/Disruptive behaviour(70)
Acutely disturbed behaviour can be managed 
with low dose antipsychotic drugs, however, 
monitoring of QTc interval, neurologic side effects 
(EPS), and sedation becomes essential. The risk 
of QTc prolongation gets further amplified, given 
the potential use of COVID-19–specific medica-
tions that themselves prolong QTc (hydroxy-
chloroquine, azithromycin), leading to a poten-
tially increased risk of torsades de pointes(71).
a) Haloperidol (2.5- 5mg) can be used orally or 
intramuscularly. Intravenous administration 
should be accompanied by ECG monitoring 
(70). 
b) Olanzapine 5-10 mg can also be considered 
either orally or parenterally. In an acutely 
disturbed patients, intramuscular (IM) is the 
preferred route of administration compared to 
intravenous (IV) route as it has minimal effect 
on QTc interval and lesser risk for EPS 
compared to haloperidol. 
c) Dexmedetomidine is alpha-2 agonist and 
reduces the release of noradrenaline and 
helps curtailing restlessness. Clonidine can 
also be used for the same reason and is more 
convenient as it's available in skin patches 
form. 
d) Valproic acid is known for its neuroprotective 
potential and can be used to control extreme 
emotional fluctuations. It also provides pro-
phylaxis against the potentially epileptogenic 
state by increasing the seizure threshold. 
However, liver function tests and platelets 
need to be constantly monitored (58). 
e) In extreme cases not responding to the above 
measures, only short acting low dose oral 
benzodiazepines (e.g., lorazepam 1- 2 mg) 
may be considered with close monitoring for 
respiratory distress and respiratory failure.
Future Research
CARDS unfortunately is still on the rise and our 
understanding on the progression and behaviour of 
the disease with respect to interventions is only 
becoming clearer day by day. Our meta-analysis 
suggests the recommendations that has been 
mentioned in the paragraphs above can be used a 
guide to curate management protocols by treating 
physicians. For each recommendation mentioned, 
it is important to consider the quality of the evidence 
reviews thoroughly before applying these recom-
mendations to specific clinical situations or policy 
decisions. No guideline or recommendations can 
consider all the compelling clinical features of 
individual patients, as they are unique. However, it 
is also unknown whether similar results can be 
found in the unselected and broad population with 
critical illness. There is, thus, a great need for well 
designed, high-quality, large, randomized trials to 
confirm the effect of COVID-19 in critically ill 
patients with CARDS.
Conclusion
CARDS is an anticipated severe complication of 
COVID-19 that requires prompt recognition and 
comprehensive multi-speciality management. 
Extensive research and studies are required to 
address the vital unanswered queries about 
treatment of mechanically ventilated patients of 
CARDS. Because of the high mortality in 
mechanically ventilated patients, the above 
recommendations and findings direct the potential 
for improvement in the management of patients with 
CARDS.
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(11) Understanding recent advances in ARDS 
treatment-
Salient features from various RCTs and clinical 
trials, that reflect recent advances and consensus in 
the understanding and management of ARDS-
(a) Multiple trials(60)(61) have failed to confirm the 
benefit of using recruitment manoeuvres in 
ARDS patients.
(b) The LUNG-SAFE study(23)(62) - Shown 
increased mortality with noninvasive ventilation 
in severe ARDS patients. 
(c) Liberal oxygen or conservative oxygen 
(LOCO ) trial(63)- Conservative oxygenation 2
strategy did not reveal increased survival 
benefits. So, hyperoxia (SpO2 >97%) and 
hypoxemia (SpO2 <90%) should be avoided.
(d) SUPERNOVA study(64)- Use of extracorporeal 
carbon dioxide removal can be utilized to enable 
ultra-protective ventilation (Tidal volume= 4 
mL/kg and P  ≤ 25 cmH O) in ARDS.PLAT 2
(e) EOLIA trial(65)- Fails to approve the superiority 
of routine use of ECMO therapy in severe ARDS 
over rescue ECMO therapy.
For the transport of intubated patients, the use of 
evacuation pods have also been described for a 
medical evacuation (66).
Neuropsychiatric symptoms in cards
Long-term outcomes of patients with ARDS are 
being increasingly recognized as important 
research targets, as many patients survive ARDS 
only to have ongoing functional and/or psycholo-
gical sequelae.
The etiopathogenesis of neuropsychiatric manifes-
tations could be either due to primary neuro-
invasion by the coronavirus 2 (SARS-CoV-2) or a 
secondary attack of inflammation by activated 
immune and inflammatory mediators. The most 
common psychiatric presentation in ICU is of 
Delirium but other neurological symptoms such as 
rigidity, myoclonus, catatonia can also be encoun-
tered.
Delirium- The prevalence of delirium in intubated 
patients is up to 80%(67) which is further 
exacerbated in CARDS patient. The risk factors 
include old age (>65yrs), medical co-morbidity, 
drugs (propofol, opiods, and high-dose benzo-
diazepines, which are routinely used during 
mechanical ventilation), hydroxychloroquine 
(67,68).
Delirium can be objectively assessed and 
monitored with 'Confusion Assessment Method for 
the ICU' scale(69).
The management comprises of:
1. Regularizing the sleep cycle
Melatonin should be used for regularizing sleep-
wake cycle in delirium owing to its short half-life, 
additional mild anti-inflammatory properties and 
no respiratory depression (69).
Benzodiazepines should be avoided (except in 
cases of delirium tremens), as cumulative doses 
run the risk of respiratory depression and may 
cause paradoxical disinhibition. Zolpidem (2.5-
5mg) is relatively safer in terms of respiratory 
functioning, but levels are increased in patients 
taking ritonavir.
2. Acute agitation/Disruptive behaviour(70)
Acutely disturbed behaviour can be managed 
with low dose antipsychotic drugs, however, 
monitoring of QTc interval, neurologic side effects 
(EPS), and sedation becomes essential. The risk 
of QTc prolongation gets further amplified, given 
the potential use of COVID-19–specific medica-
tions that themselves prolong QTc (hydroxy-
chloroquine, azithromycin), leading to a poten-
tially increased risk of torsades de pointes(71).
a) Haloperidol (2.5- 5mg) can be used orally or 
intramuscularly. Intravenous administration 
should be accompanied by ECG monitoring 
(70). 
b) Olanzapine 5-10 mg can also be considered 
either orally or parenterally. In an acutely 
disturbed patients, intramuscular (IM) is the 
preferred route of administration compared to 
intravenous (IV) route as it has minimal effect 
on QTc interval and lesser risk for EPS 
compared to haloperidol. 
c) Dexmedetomidine is alpha-2 agonist and 
reduces the release of noradrenaline and 
helps curtailing restlessness. Clonidine can 
also be used for the same reason and is more 
convenient as it's available in skin patches 
form. 
d) Valproic acid is known for its neuroprotective 
potential and can be used to control extreme 
emotional fluctuations. It also provides pro-
phylaxis against the potentially epileptogenic 
state by increasing the seizure threshold. 
However, liver function tests and platelets 
need to be constantly monitored (58). 
e) In extreme cases not responding to the above 
measures, only short acting low dose oral 
benzodiazepines (e.g., lorazepam 1- 2 mg) 
may be considered with close monitoring for 
respiratory distress and respiratory failure.
Future Research
CARDS unfortunately is still on the rise and our 
understanding on the progression and behaviour of 
the disease with respect to interventions is only 
becoming clearer day by day. Our meta-analysis 
suggests the recommendations that has been 
mentioned in the paragraphs above can be used a 
guide to curate management protocols by treating 
physicians. For each recommendation mentioned, 
it is important to consider the quality of the evidence 
reviews thoroughly before applying these recom-
mendations to specific clinical situations or policy 
decisions. No guideline or recommendations can 
consider all the compelling clinical features of 
individual patients, as they are unique. However, it 
is also unknown whether similar results can be 
found in the unselected and broad population with 
critical illness. There is, thus, a great need for well 
designed, high-quality, large, randomized trials to 
confirm the effect of COVID-19 in critically ill 
patients with CARDS.
Conclusion
CARDS is an anticipated severe complication of 
COVID-19 that requires prompt recognition and 
comprehensive multi-speciality management. 
Extensive research and studies are required to 
address the vital unanswered queries about 
treatment of mechanically ventilated patients of 
CARDS. Because of the high mortality in 
mechanically ventilated patients, the above 
recommendations and findings direct the potential 
for improvement in the management of patients with 
CARDS.
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Masa pulsátil en el cuello: arteria subclavia sobre costilla cervical
Throbbing mass in the neck:  subclavian artery on the cervical rib
1,* 1,%Ana M. García-Rodríguez o-Avilés2,#, Miguel J. Sánchez-Velasco ,  María C. Aldud
Resumen
Una masa pulsátil en el triángulo posterior del cuello puede inducir preocupación 
cuando crece y comienza a molestar. Se presenta caso de mujer joven, que 
consulta por dicho motivo, en la que se identifica una arteria subclavia 
verticalizada por coexistencia con costilla cervical. Al ser, por el momento, 
asintomática únicamente requirió una actitud preventiva, además de un 
seguimiento evolutivo ante la posibilidad del desarrollo de un cuadro compresivo 
por el síndrome del desfiladero torácico y/o un aneurisma arterial.
Palabras clave: costilla cervical, arteria subclavia, síndrome del desfiladero 
torácico.
Abstract
A throbbing mass in the rear triangle of the neck can be of concern when it grows 
and begins to disturb. There is a case of a young woman, who consults for this 
reason, in which a verticalized subclavian artery is identified by cervical rib. Being, 
for the time being, asymptomatic only required a preventive attitude, in addition to 
an evolutionary follow-up to the possibility of the development of a compression 
picture by thoracic gorge syndrome and/ or an arterial aneurysm.
Keywords: cervical rib, subclavian artery, thoracic outlet syndrome.
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Introducción
Es importante familiarizarse con algunas malforma-
ciones óseas como la costilla cervical, anomalía 
costal más frecuente, que puede inducir cambios 
de conformación en el cuello. Aunque lo habitual es 
que sea asintomática y un hallazgo casual 
radiológico, puede producir masas induradas 
además de otros síntomas (1-3). Una masa pulsátil 
es una forma poco usual de presentación (4-6), lo 
que es de cardinal importancia identificar para 
prevenir complicaciones potencialmente graves 
(7).
El diagnóstico diferencial incluye una malformación 
vascular, un tumor del cuerpo carotídeo o un 
desarrollo aneurismático. Se descartan quistes, 
linfangiomas, adenopatías y/o lipomas por no 
concordancia en las características del propio 
tumor o por la localización anatómica cervical (8).
Se presenta el caso de paciente joven que consulta 
por masa pulsátil molesta en el cuello a la que se 
identifica la arteria subclavia izquierda verticalizada 
por costilla cervical. La actitud generada es la 
instrucción sobre hábitos de vida para evitar la 
consecución del síndrome del desfiladero torácico 
(9,10). Además, se efectúa seguimiento reglado, 
por nuestra parte, para detección de un posible 
desarrollo aneurismático en el tiempo (7).
Reporte de caso
Mujer de 24 años, con buen estado general, que 
acude a la consulta de Atención Primaria (AP) por 
una masa en cuello, que refiere tener de toda la 
vida, pero nota más voluminosa desde hace unos 
meses, late y molesta, sin síncopes ni mareos 
asociados. No se reseñan antecedentes 
personales ni familiares de interés.
En la exploración se evidencia una masa pulsátil a 
nivel supraclavicular izquierdo, en triángulo 
posterior cervical, con un aspecto de ambas 
extremidades (desarrol lo muscular, color, 
temperatura y distribución de vello y faneras) 
uniforme. Para comprobar la integridad del flujo 
vascular de la extremidad se efectúan las 
maniobras de Adson (persiste pulso radial con la 
abducción del brazo y la rotación lateral del cuello 
hacia el lado explorado) y de Wright (abducción de 
la extremidad hasta los 180 º en rotación externa) 
que fueron negativas; la tensión arterial bilateral, la 
auscultación y el electrocardiograma también 
fueron normales. (Figura 1)
En la misma consulta se realiza una ecografía con 
ecógrafo de bolsillo y sonda de alta frecuencia (7,5 
MHz): se observa flujo turbulento bicolor al aplicar 
el Doppler, con formaciones irregulares rodeando 
luz (Figura 2).
Se plantea diagnóstico diferencial con paraganglio-
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